PCR167 Targeted Literature Review to Understand the Patient Experience of Essential Thrombocythemia and to Evaluate Existing Clinical Outcome Assessment Measures

Autor: Lloyd-Price, L, Yang, X, McQuarrie, K, Gyorkey, J, Howerter, A, Hudgens, S

Publikováno v: In Value in Health June 2024 27(6) Supplement:S327-S327

Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study

Autor: Chi, K.N., Merseburger, A.S., Cella, D., Chowdhury, S., Basch, E., Miladinovic, B., Uemura, H., Agarwal, N., Bjartell, A., Chung, B.H., Naini, V., Juárez Soto, Á., Pereira de Santana Gomes, A.J., Deprince, K., Given, R., Dearden, L., McQuarrie, K., Özgüroğlu, M., TITAN investigators, Ye, D., Lopez-Gitlitz, A.

Background: In the phase 3 TITAN study, the addition of apalutamide to androgen deprivation therapy (ADT) significantly improved the primary endpoints of overall survival and radiographic progression-free survival in patients with metastatic castrati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6a7de5d6a8f8ea2e19d3254a1828b2fd

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Improvements in Measures of Work Productivity/Interference and General Health Status with Sirukumab Treatment in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment

Autor: Takeuchi, T, Karpouzas, G, Thorne, C, McQuarrie, K, Sheng, S, Xu, W, Peterson, S, Ganguly, R, Han, C, Fei, K, Hsu, B

Publikováno v: 44. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 30. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 26. Jahrestagung der Gesellschaft für Kinder-und Jugendrheumatologie (GKJR); 20160831-20160903; Frankfurt am Main; DOCRA.43 /20160829/

Background: Treatment-related improvements in the ability to perform work and general health status are key outcomes from the perspective of a patient with rheumatoid arthritis (RA). Sirukumab is a human monoclonal antibody that selectively binds to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75654b6e46e2dfe15618304507ecf545

O6 - Patient-reported outcomes (PROs) From TITAN: A phase 3, randomized, double-blind study of apalutamide (APA) versus placebo (PBO) added to androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC)

Autor: Agarwal, N., Mcquarrie, K., Bjartell, A., Chowdhury, S., Pereira De Santana Gomes, A.J., Chung, B.H., Özgüroğlu, M., Juárez Soto, Á., Merseburger, A.S., Uemura, H., Ye, D-W., Given, R., Miladinovic, B., Dearden, L., Deprince, K., Naini, V., Lopez-Gitlitz, A., Chi, K.N.

Publikováno v: In European Urology Supplements November 2019 18(11):e3413-e3414